Abstract: Techniques for using data indicating if a gas regulator supplying gas at a regulated pressure to a gas meter (e.g., the gas meter of a house or business) within a gas distribution system has one or more lock-up failure events or venting events, wherein gas is vented to the atmosphere. The data may identify the identity of gas regulators at which the lock-up failure events or venting events occurred. Based at least in part on the identified gas regulators, a number of gas regulators having at least one of lock-up failure events or venting events that are connected to a same gas supply line may be identified. If the number of gas regulators having at least one of lock-up failure events or venting events on the identified gas supply line exceeds a threshold number this may indicate the presence of debris in the gas supply. Remedial steps may be taken, and the situation may be monitored and reassessed.

Abstract: Techniques detect a low gas-pressure condition within a region without the use of pressure sensors. In an example, gas usage at a service site is disaggregated to show use by individual appliances. A flowrate of gas at an appliance (e.g., a gas hot water tank) having a generally fixed-rate of gas-consumption is determined. Based at least in part on the flowrate of gas at the appliance, and an historical gas flowrate at that appliance, it is determined if gas pressure at the service site is lower than expected. In an example, failure of the appliance to use its typical fixed-flowrate may indicate low gas pressure at the service site. Information is obtained from a second gas meter at a second service site. Based on the gas pressure at the first and second service sites being lower than expected, a low gas pressure situation may exist in a regional area.

Abstract: Techniques determine if an appliance having a fixed-rate of gas-consumption is degrading over time. In one example, a flowrate of gas at a service site is obtained. The flowrate of gas is disaggregated to obtain a flowrate of gas corresponding to an appliance having a generally fixed-rate of gas-consumption. The flowrate of gas of the appliance is compared to historical gas consumption by the appliance. Based at least in part on the comparing, it may be determined that performance of the appliance has changed over time. For example, the gas consumption of a hot water tank may increase due to mineral build-up in the bottom of the tank. Responsive to the determined degradation of the appliance, warnings may be sent, repairs may be made, and/or appliance(s) may be replaced.

Abstract: The present invention is directed to pharmaceutical compositions comprising a plurality of taste-masked non-opioid analgesic/opioid analgesic drug-containing microparticles, dosage forms comprising such pharmaceutical compositions (such as an orally disintegrating tablet), and methods of making the pharmaceutical compositions and dosage forms of the present invention. Dosage forms comprising the pharmaceutical compositions of the present invention are improved homogeneous blends of non-opioid and opioid analgesics which provide for more convenient and palatable administration of drug combinations, for example for treating pain.

Abstract: The present invention is directed to pharmaceutical compositions comprising a plurality of taste-masked non-opioid analgesic/opioid analgesic drug-containing microparticles, dosage forms comprising such pharmaceutical compositions (such as an orally disintegrating tablet), and methods of making the pharmaceutical compositions and dosage forms of the present invention. Dosage forms comprising the pharmaceutical compositions of the present invention are improved homogeneous blends of non-opioid and opioid analgesics which provide for more convenient and palatable administration of drug combinations, for example for treating pain.

Abstract: The present invention is directed to pharmaceutical compositions comprising a plurality of taste-masked high-dose/low-dose drug-containing microparticles, dosage forms comprising such pharmaceutical compositions (such as an orally disintegrating tablet), and methods of making the pharmaceutical compositions and dosage forms of the present invention. Dosage forms comprising the pharmaceutical compositions of the present invention are improved homogeneous blends of high-dose and low-dose drugs which provide for more convenient and palatable administration of drug combinations, for example for treating pain, hyperglycemia, cardiovascular disease, and allergies.

Abstract: A tablet that rapidly disintegrates in the oral cavity comprising a compressed blend of rapidly dispersing microgranules prepared by granulating a sugar alcohol or a saccharide or a mixture thereof having an average particle size less than about 30 microns and a disintegrant, and a taste-masked microcapsule containing at least one drug, the microcapsule being prepared by granulating a pharmaceutically acceptable formulation comprising at least one drug in a therapeutically effective amount and at least one polymeric binder that improves resilience of the microgranules, wet milling the granulated mass, and microencapsulating the milled granules to provide microcapsules.

Abstract: The apparatus is an electronic speed control for farm machines. A microprocessor is fed data on the tractor engine speed, the tractor ground speed, and the manual speed lever setting, and electronically matches the desired ground speed to the engine speed to prevent stalling the engine. Ground speed is controlled by using the microprocessor to electrically vary a control valve that replaces the usual mechanical linkage between the speed control lever and the hydraulic pumps driving the hydraulic wheel motors.

Abstract: A unit dosage form, such as a capsule or the like, for delivering a skeletal muscle relaxant, such as cyclobenzaprine hydrochloride, into the body in an extended or sustained release fashion comprising one or more populations of drug-containing particles (beads, pellets, granules, etc.) is disclosed. At least one bead population exhibits a pre-designed sustained release profile. Such a drug delivery system is designed for once-daily oral administration to maintain an adequate plasma concentration—time profile, thereby providing relief of muscle spasm associated with painful musculoskeletal conditions over a 24 hour period.